M

Mass General Brigham

Early-stage life science venture investor

RN – Clinic

Full-TimeUpdated on 10/23/2026
$37.69 - $89.59/hr+ Differentials + Premiums + Bonuses
Mid
Bachelor's
Nantucket, MA, USA
In PersonOnsite in Nantucket; may attend meetings on or off the island.
Medical, Clinical & VeterinaryNursing & Frontline Patient Care

About the job

Requirements
  • Knowledge of basic nursing principles.
  • Good computer skills, including knowledge of Microsoft Office, electronic medical record systems, and medical office practice applications.
  • Effective analytical skills.
  • Ability to tactfully communicate with internal and external customers.
  • Ability to use fingers and hands to operate department-related equipment, including telephone, calculator, fax, copier, and scanner.
  • Ability to frequently bend, using back and knees.
  • Ability to stand and walk 40% and sit 60% of the time; frequently climb, bend, reach, stoop, squat, lift objects from five to fifty pounds, and move patients via wheelchair or stretcher; independently lift five to twenty-five pounds.
  • Ability to present themselves in a professional manner.
  • Ability to develop rapport with providers, clinical staff, patients, and families.
  • Ability to work independently and cooperatively with managers, employees, vendors, contractors, and other agencies; be flexible and highly organized; make independent decisions in response to operational issues in medical office environments; and know basic principles of practice and departmental management.
  • Graduate of an accredited nursing school.
  • Current Registered Nurse licensure in Massachusetts.
  • BLS/CPR certification is required within one week of hire; AHA and ARC are accepted.
  • Other certifications as needed to perform clinical tasks in the clinical setting.
  • Must be available to work some weekends, with hours determined by practice needs.
  • Overtime may be required to complete assigned work.
  • Must be available to work in the case of a declared hospital emergency.
  • May be required to attend meetings on or off the island.
Responsibilities
  • Participate in day-to-day clinical activities as a registered nurse to ensure a patient-focused, quality environment of care, and ensure compliance with NCH/NCMG best practices and policies.
  • Maintain a safe environment for patients, family members, and staff.
  • Collaborate with practice and hospital leadership to identify current and future practice needs, participate in developing work plans, implement changes supporting primary care and specialty models, and participate in assigned special projects.
  • Promote an environment sensitive to the culturally diverse needs of patients and staff.
  • Facilitate positive working relationships among MGH/NCMG and NCH departments.
  • Comply with and monitor adherence to HIPAA policies and procedures for protected health information.
  • Create and maintain practice-operation policies, procedures, and guidelines, including those for point-of-care testing, new medications and therapies, and patient flow; monitor adherence.
  • Serve as a departmental resource for Joint Commission and other regulatory site visits, and ensure the environment of care is maintained.
  • Implement quality measures as directed by MGH/NCMG and NCH Quality teams, and participate in government and private insurer programs to support practice-flow quality goals.
  • Meet hand-hygiene and other infection-control practices.
  • Maintain clinical skills through self-directed practice and self-examination as required for licensure.
  • Handle calls from patients or representatives seeking medical information or attention; facilitate appointment scheduling, answer care questions, and provide telephone health education.
  • Participate in the daily morning huddle to identify clinical care concerns and needs for scheduled patients and families.
  • Help process medication refills.
  • Conduct timely patient callbacks and follow-up calls, documenting interactions in the EHR.
  • Help the office team obtain required medical records, consults, and test results.
  • Complete medical and treatment pre-authorizations in a timely manner.
  • Refer patients to outside institutions when clinical expertise is needed.
  • Assist providers and office staff in scheduling required appointments using the EMR and other scheduling systems.
  • Assist providers with EMR in-basket management.
  • Administer immunizations within established practice guidelines.
  • Complete pre-visit comprehensive assessments, intake, and histories for new patients.
  • Room patients and prepare patients and rooms for providers by gathering supplies and opening the clinical record with the appropriate template.
  • Review and document relevant clinical information in patient records, including chief complaint, reason for visit, nursing assessment, medication reconciliation, patient/family/social history including smoking status, health-maintenance status, nursing care, vaccine status and administration, vital signs, fall screening for patients over 65, allergies, and preferred pharmacy.
  • Complete screening and evaluation forms, including PEDS and postpartum screenings.
  • Review PROMS questionnaires.
  • Confirm patient consents for treatment and care, including surgical procedures, labor and delivery care, and sterilization; help provide patient education with providers as needed.
  • Ensure required insurance forms are reviewed and signed by patients, including Medicare physical and medication/vaccine waivers.
  • Teach and educate patients and families using current standardized teaching tools and handouts.
  • Assist providers with treatments and screenings.
  • Complete medication and treatment pre-authorizations.
  • Complete nurse visits promptly, providing and recording assessment and treatment data, consulting providers as required, and completing coding in the EHR according to documented industry standards and Partners policy.
  • Send and respond to clinical messages promptly.
  • Assist other nurses as needed.
  • Keep rooms adequately stocked.
  • Assist patients in and out of wheelchairs and provide other assistance as needed.
  • Perform telephone triage by responding promptly to patient calls, collecting sufficient information about the presenting problem and medical history, providing medical advice within the scope of practice, facilitating appointments based on necessity, accurately documenting encounters in the EMR, and maintaining the EMR work queue.
  • Perform other duties as assigned to support optimal functioning of NCMG and specialty offices.
Desired Qualifications
  • A minimum of three years of relevant clinical experience is preferred.

About the company

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

Company Size

1-10

Company Stage

N/A

Total Funding

$1.9B

Headquarters

Cambridge, Massachusetts

Founded

2008

Get referred to Mass General Brigham

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Mass General Brigham reported $15 million operating income through June 30, 2026.
  • Outpatient growth and higher-acuity inpatient volumes drove 7% revenue growth in Q3 FY26.
  • Abcuro's 2026 financing extends a potential registrational trial, validating MGB Ventures sourcing.

What critics are saying

  • Brigham nurses authorized an indefinite strike on September 24, 2026; operations face disruption.
  • MGB refused negotiations after July strikes and lockouts, deepening staffing instability into 2027.
  • The September 2026 antidiscrimination case and website-data settlement reinforce litigation overhangs.

What makes Mass General Brigham unique

  • Mass General Brigham controls flagship Boston hospitals and a research-to-venture pipeline.
  • MGB Ventures backed Abcuro's $66 million Series D in August 2026.
  • Its $22.8 billion 2025 operating revenue funds clinical, academic, and commercialization depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Flexible Work Hours
  • Remote Work Options
  • Hybrid Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Family Planning Benefits
  • Fertility Treatment Support

Company News

Business Wire
Oct 25th, 2026
Nocion Therapeutics Extends Series B Financing to $93 Million to Support Late-Stage Development of Taplucainium in Chronic Cough

Nocion Therapeutics, Inc. today announced that it has raised $23 million from existing investors in an extension of its Series B, bringing the total amount o...

PR Newswire
Oct 1st, 2026
Mass General Brigham postpones annual summit after nurses plan picket over $2.3B hospital system refusing fair contracts

Mass General Brigham has postponed its annual summit after nurses and clinicians represented by the Massachusetts Nurses Association issued a picket notice for the 7 October event in Somerville. The postponement follows a 93% strike authorisation vote by Brigham and Women's Hospital nurses and protests against MGB executives. MGB nurses and clinicians have been campaigning against the hospital system following strikes and a lockout in July. Brigham nurses are seeking contract improvements including limits on temporary nurses, affordable health insurance, and fair compensation. MGB Home Care clinicians are negotiating their first union contract. MGB reported $22.8 billion in operating revenue and $2.39 billion in profits for fiscal year 2025. The system has refused to return to negotiations since August.

ABCuro
Aug 18th, 2026
Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis.

Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis. * Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 * Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with less severe IBM in the previous Phase 2/3 MUSCLE study * Series D financing led by New Leaf Venture Partners, joined by Abcuro's existing investors and new investor Rock Springs Capital Newton, Massachusetts, August 18, 2026 - Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participation of existing investors including funds managed by abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay and joining the round is Rock Springs Capital. Proceeds from the Series D financing will support a new potentially registrational clinical study of ulviprubart, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of patients with less severe IBM. Abcuro has been in discussions with the U.S. Food and Drug Administration (FDA) and expects to initiate the new study in the fourth quarter of this year. Assuming positive results from the clinical study, Abcuro plans to file a biologics license application (BLA). "We are pleased to have this opportunity to further evaluate ulviprubart in patients with IBM, a devastating progressive disease," said Alex Martin, Chief Executive Officer of Abcuro. "We have begun preparations to initiate a clinical trial in the fourth quarter of 2026 as we continue our work to develop an effective treatment option in an indication where there is no approved therapy. We remain dedicated to the IBM community and thank our investors who share our conviction in ulviprubart's potential." Results from the recent Phase 2/3 MUSCLE study of ulviprubart in patients with IBM were presented at the 6th Global Conference on Myositis (GCOM) meeting in March 2026. The clinical data, while not statistically significant, showed a trend toward slowing of disease progression relative to placebo as measured by IBMFRS in the overall patient population, including a 50% slowing of disease progression in a pre-defined analysis of less severe IBM patients with IBMFRS >29. Ulviprubart was also shown to have a favorable safety and tolerability profile compared to placebo. "The MUSCLE study provided encouraging data in a pre-defined analysis of patients with less severe disease, underscoring ulviprubart's unique mechanism of targeting highly differentiated cytotoxic T cells expressing KLRG1," said Namita Goyal, MD, Chief of the Neuromuscular Division at the University of California, Irvine School of Medicine. "IBM continues to be a disabling, progressive disease with no approved treatment, affecting tens of thousands of patients around the world. Ulviprubart demonstrated clear and meaningful slowing of disease progression in less severe disease, offering real hope to patients, care partners, and the physicians who treat them." "There is a significant unmet need for an approved treatment for IBM. The expertise and persistence of the Abcuro team to understand this disease and the role ulviprubart may have in targeting these cytotoxic T cells that are associated with muscle destruction was key to our continued investment of the company. We are excited to work closely with the company as it moves forward in this next chapter," said Ron Hunt, Co-Founder and Managing Director of New Leaf Venture Partners. About Ulviprubart Ulviprubart is a first-in-class, potent, monoclonal antibody that targets pathogenic T cells that express killer cell lectin-like receptor G1 (KLRG1) on their cell surface, referred to as KLRG1+ T cells. Ulviprubart is designed to selectively target and deplete well-differentiated cytotoxic KLRG1+ T cells where KLRG1 is highly expressed, while sparing other immune cells, which may offer improvements in safety and tolerability as compared to other T cell depleting approaches. About Inclusion Body Myositis (IBM) IBM is a rare, debilitating and relentlessly progressive chronic autoimmune muscle disease with no approved pharmacologic treatments and a significant unmet need. It is mediated by highly differentiated T cells that are chronically or aberrantly overstimulated and can have detrimental long-term effects including destruction of healthy muscle tissue. People living with IBM progressively lose muscle function, including loss of grip, dexterity and mobility. Based on published epidemiology literature, the ICD-10 code for IBM and an estimate for those misdiagnosed or undiagnosed, Abcuro estimate there are approximately 40,000 patients diagnosed with IBM in the United States and Abcuro estimate the prevalence of IBM to be approximately 35,000 patients across major European countries and Japan. Abcuro estimate that patients with less severe disease represent nearly 50% of the overall IBM patient population. About Abcuro Abcuro is a clinical stage biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic. Abcuro believe that by selectively targeting and depleting highly cytotoxic T cells, which are key drivers of chronic inflammation and damage, Abcuro can advance its mission to deliver potentially life-transforming, disease-modifying therapies to patients facing these devastating conditions. The company's lead program, ulviprubart, is currently being evaluated in inclusion body myositis (IBM). For more information, visit Abcuro on LinkedIn and at abcuro.com.

Claris Bio
Jul 29th, 2026
07-28-2026 Press Releases from Claris Bio

Latest Press Releases from Claris Bio.

Fierce Healthcare
Jun 15th, 2026
InStride Health lands $30M series C to expand pediatric mental health services

InStride Health, a provider of virtual specialty mental healthcare for children and young adults, has raised $30 million in Series C funding led by Echo Health Ventures and FMZ Ventures. Existing investors including .406 Ventures, General Catalyst and Mass General Brigham Ventures also participated. Founded in 2021, InStride offers insurance-based treatment for anxiety and obsessive-compulsive disorder in patients aged seven to 24. The company pairs each patient with a care team comprising a psychiatrist, therapist and exposure coach, providing support through text and a mobile application. InStride has treated 5,000 patients across 17 states, primarily on the East Coast and Texas. The company published data showing 97% of patients demonstrated clinical improvement, with a 53% average reduction in anxiety scores. The funding will support expansion into new markets and strengthen payer partnerships.